IMMUNOGEN

ImmunoGen, Inc.
Investor Relations Department
830 Winter Street
Waltham, MA 02451
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: IMGN	
Last Trade:	4.34
Trade Time:	4:00 PM ET Apr 28, 2017
Change:	-0.01 (-0.230%)
Day Range	4.28 - 4.40
52-Week Range	1.51 - 6.84
Volume	905,006

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing in combination regimens for earlier-stage disease. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla®, in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX... (more)

Stock Performance

Press Releases [View all]

Apr 21, 2017
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2017 Financial Results

Mar 12, 2017
ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data at the Society of Gynecologic Oncology Annual Meeting

Mar 1, 2017
ImmunoGen Announces Presentations at AACR Annual Meeting

Feb 17, 2017
ImmunoGen Reports Recent Progress and Operating Results for Six-Month Period and Quarter Ended December 31, 2016

Feb 2, 2017
ImmunoGen Announces Webcasts of Presentations at Upcoming Investor Conferences

Upcoming Events [View all]

May 5, 2017 8:00 AM ET
ImmunoGen quarterly update conference call

Financials [View all]

First Quarter Financial Results

Aug 25, 2016
Annual Report (10-K)

Apr 28, 2017
Proxy Statement (DEF 14A)

Nov 4, 2016
Quarterly Report (10-Q)

May 4, 2016
Quarterly Report (10-Q)

Feb 4, 2016
Quarterly Report (10-Q)